Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9145389 | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jun, 2020
(3 years ago) | |
US6462058 | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jun, 2020
(3 years ago) | |
US7285668 | TAKEDA PHARMS USA | Process for the crystallization of (R)- or (S)-lansoprazole |
Jun, 2020
(3 years ago) | |
US6664276 | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jan, 2023
(1 year, 2 months ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6939971 | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jun, 2020
(3 years ago) | |
US7285668 (Pediatric) | TAKEDA PHARMS USA | Process for the crystallization of (R)- or (S)-lansoprazole |
Dec, 2020
(3 years ago) | |
US6939971 (Pediatric) | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Dec, 2020
(3 years ago) | |
US6462058 (Pediatric) | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Dec, 2020
(3 years ago) | |
US6664276 (Pediatric) | TAKEDA PHARMS USA | Benzimidazole compound crystal |
Jul, 2023
(8 months ago) | |
US8784885 | TAKEDA PHARMS USA | Controlled release preparation |
Oct, 2023
(6 months ago) | |
US8722084 | TAKEDA PHARMS USA | Controlled release preparation |
Oct, 2023
(6 months ago) | |
US8722084 (Pediatric) | TAKEDA PHARMS USA | Controlled release preparation |
Apr, 2024
(10 days ago) | |
US8784885 (Pediatric) | TAKEDA PHARMS USA | Controlled release preparation |
Apr, 2024
(10 days ago) | |
US8461187 | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jan, 2026
(1 year, 8 months from now) | |
US9238029 | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jan, 2026
(1 year, 8 months from now) | |
US9011926 | TAKEDA PHARMS USA | Method for producing granules |
Feb, 2026
(1 year, 9 months from now) | |
US8461187 (Pediatric) | TAKEDA PHARMS USA | Multiple PPI dosage form |
Jul, 2026
(2 years from now) | |
US7790755 | TAKEDA PHARMS USA | Controlled release preparation |
Aug, 2026
(2 years from now) | |
US8105626 | TAKEDA PHARMS USA | Granules containing acid-unstable chemical in large amount |
Sep, 2026
(2 years from now) | |
US7790755 (Pediatric) | TAKEDA PHARMS USA | Controlled release preparation |
Feb, 2027
(2 years from now) | |
US8105626 (Pediatric) | TAKEDA PHARMS USA | Granules containing acid-unstable chemical in large amount |
Mar, 2027
(2 years from now) | |
US8871273 | TAKEDA PHARMS USA | Method for producing granules |
Jan, 2028
(3 years from now) | |
US8173158 | TAKEDA PHARMS USA | Methods of treating gastrointestinal disorders independent of the intake of food |
Mar, 2030
(5 years from now) | |
US8173158 (Pediatric) | TAKEDA PHARMS USA | Methods of treating gastrointestinal disorders independent of the intake of food |
Sep, 2030
(6 years from now) | |
US9233103 | TAKEDA PHARMS USA | Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy |
Mar, 2032
(7 years from now) |
Dexilant is owned by Takeda Pharms Usa.
Dexilant contains Dexlansoprazole.
Dexilant has a total of 25 drug patents out of which 13 drug patents have expired.
Expired drug patents of Dexilant are:
Dexilant was authorised for market use on 30 January, 2009.
Dexilant is available in capsule, delayed release;oral dosage forms.
Dexilant can be used as use of dexlansoprazole in patients taking clopidogrel without meaningful cyp2c19 interactions, healing of all grades of erosive esophagitis (ee) for up to 8 weeks, maintain healing of erosive esophagitis (ee) for up to 6 months, treatment of heartburn associated with non-erosive gastroesophageal reflux disease (gerd) for 4 weeks, for healing of all grades of erosive esophagitis (ee), to maintain healing of ee and relief of heartburn.
The generics of Dexilant are possible to be released after 05 March, 2032.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Jan 30, 2012 |
New Patient Population(NPP) | Jul 08, 2019 |
Pediatric Exclusivity(PED) | Jul 30, 2012 |
Drugs and Companies using DEXLANSOPRAZOLE ingredient
Market Authorisation Date: 30 January, 2009
Treatment: Treatment of heartburn associated with non-erosive gastroesophageal reflux disease (gerd) for 4 weeks; For healing of all grades of erosive esophagitis (ee); Healing of all grades of erosive esophagit...
Dosage: CAPSULE, DELAYED RELEASE;ORAL